25992 Long-term efficacy of tildrakizumab 100 mg by PASI 75/90/100 and PGA in a pooled analysis of reSURFACE 1 and reSURFACE 2 through up to 4 years of treatment
- Resource Type
- Abstract
- Source
- In
Journal of the American Academy of Dermatology September 2021 85(3) Supplement:AB79-AB79 - Subject
- Language
- ISSN
- 0190-9622